Table 4.
Odds ratio preference results estimated from regression models (n = 548).
| Variable | Odds Ratio (OR) | 95% CI | P Value | |
|---|---|---|---|---|
| Number of Serotypes Included | 13 serotypes | Reference | Reference | |
| 15 serotypes | 1.1 | (1.0, 1.2) | .01 | |
| 20 serotypes | 1.4 | (1.3, 1.5) | <.001 | |
| Effectiveness Against Serotype 3 | 15% | Reference | Reference | |
| 30% | 1.1 | (1.0, 1.2) | .07 | |
| 60% | 1.4 | (1.2, 1.6) | <.001 | |
| 80% | 1.8 | (1.5, 2.1) | <.001 | |
| 95% | 1.9 | (1.6, 2.2) | <.001 | |
| Immune Response for the Serotypes Covered in PCV13 | Comparable to PCV13 on 8 of the 13 shared serotypes with 5 serotypes with inferior immune response | Reference | Reference | |
| Comparable to PCV13 on 10 of the 13 shared serotypes with 3 serotypes with inferior immune response | 1.1 | (1.0, 1.3) | .17 | |
| Comparable to PCV13 on all 13 of the shared serotypes | 1.7 | (1.5, 2.0) | <.001 | |
| Comparable to PCV13 on all 13 of the 13 shared serotypes with 1 serotype with superior immune response | 3.0 | (2.5, 3.6) | <.001 | |
| Percent Coverage of IPD | Covers serotypes accounting for 17% of the current residual IPD burden | Reference | Reference | |
| Covers serotypes accounting for 38% of the current residual IPD burden | 1.6 | (1.4, 1.8) | <.001 | |
| Covers serotypes accounting for 53% of the current residual IPD burden | 2.1 | (1.8, 2.4) | <.001 | |
| Acute Otitis Media (AOM) indication | No AOM indication | Reference | Reference | |
| AOM indication supported by AOM efficacy data from PCV7; no data on efficacy of newer, non-PCV7 serotypes to AOM | 1.7 | (1.6, 1.9) | <.001 | |
| AOM indication supported by a clinical trial specific to the new vaccine | 2.0 | (1.8, 2.3) | <.001 |
Abbreviations: AOM: Acute otitis media; CI: Confidence interval; HCP: Healthcare provider; IPD: Invasive pneumococcal disease; OR: Odds ratio; PCV: Pneumococcal conjugate vaccine; SD: Standard deviation; Q1: First quartile; Q3: Third quartile.